Matthew Gall serves as Executive at iTeos Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Matthew Gall has executed 6 insider transactions totaling $404.6K, demonstrating a bearish approach to their equity position. Their most recent transaction on Aug 29, 2025 involved transacting 89,429 shares valued at $0.
Matthew Gall currently holds 60,429 shares of iTeos Therapeutics, Inc. (ITOS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Gall has been a net seller of ITOS stock. They have purchased $172.3K and sold $232.3K worth of shares.
Matthew Gall's most recent insider trade was on Aug 29, 2025, when they sold 89,429 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Oct 12, 2023 | ITOS | $41.9K | Purchase | 5,000 | $8.37 | Discretionary |
| Dec 27, 2021 | ITOS | $232.3K | Sale | 5,000 | $46.45 | Discretionary |
| Oct 11, 2021 | ITOS | $88.9K | Option Exercise | 14,429 | $6.16 | Discretionary |
| Jun 16, 2021 | ITOS | $130.4K | Purchase | 5,000 | $26.09 | Discretionary |